Researchers report administering immunotherapy treatment prior to surgery for those with recurring glioblastoma brain cancer is more effective that using the treatment after surgery.
Researchers report they have discovered an innovative method that may stop the spread of glioblastoma multiforme.
Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer.
Combining an antibiotic drug that targets glutamine with the ketogenic diet helps kill glioblastoma cancer cells, reversing symptoms of the disease and improving survivability in mouse models.
Researchers at MIT have developed a new drug delivering nanoparticle that is able to cross the blood-brain barrier. The nanoparticles carry two different drugs that can help shrink tumors and prevent them from growing back.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.